RxDoctor Payments Data

Klariz Tucker, MD

Internal Medicine · Columbia, SCNPI 1790302362

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 91 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$384
  • AbbVie$254
  • Amgen$202
  • Novo Nordisk$195
  • Lilly USA, LLC$151
  • Pfizer$143
  • plus $505 from 14 others

What the payments were for

  • Food & beverage$1,835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$36,193
Medicare patients
96
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$33,800
MounjaroTirzepatide28$29,818
EliquisApixaban21$17,662
EntrestoSacubitril/Valsartan12$8,201
SynthroidLevothyroxine Sodium22$2,277
Rosuvastatin Calcium56$802
Mirtazapine32$582
Omeprazole35$540
Fluticasone Propionate37$482
Gabapentin29$481
Atorvastatin Calcium56$456
Olmesartan Medoxomil18$432
Duloxetine Hcl19$315
Losartan Potassium40$312
Levothyroxine Sodium47$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$195$33,80019 claims
Lilly USA, LLCMounjaro$151$29,81828 claims
PfizerEliquis$143$17,66221 claims
AbbVieSynthroid$254$2,27722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →